Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mipomersen in severe LDL-hypercholesterolemia patients receiving regular LDL-apheresis
2011-002539-24Phase 2Terminated
- Sponsor
- LMU Klinikum
- Start
- Feb 2012
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, single-arm trial of mipomersen in hypercholesterolemia and atherosclerosis, sponsored by LMU Klinikum. Primary endpoint: Primary efficacy endpoint. Started Feb 2012; status: terminated.
02
Drugs
mipomersen
03
Conditions
hypercholesterolemiaatherosclerosis
Beyond the preview
Go deeper on 2011-002539-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002539-24.